Dose Escalation Study of Liposomal Paclitaxel Plus Capecitabine in Chinese Patients With Advanced Gastric Carcinoma

Inclusion Criteria:

* Age: 18 to 75
* Histologically or cytologically documented gastric adenocarcinoma and esophagus-gastro adenocarcinoma of metastatic or advanced stages with/without measurable tumor according to RECIST standard
* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1
* Patients who are expected to live at least 3 months
* No prior systemic chemotherapy with advanced stereo- tumor before the recruitment(recidivist/ metastatic without perioperative chemotherapy at least 6m)
* No Previous anaphylactic reaction to hormone
* Obtaining informed consent
* Patients may comply with the study protocol
* Laboratory tests: Absolute neutrophil count (ANC) ≥2,000/mm³, Platelet count ≥100,000/mm³, Hemoglobin ≥9.0 g/dL, Serum creatinine≤1.5 x the institutional upper limit of normal (ULN), Creatinine clearance≥50ml/min，Total bilirubin≤1.5 x the institutional upper limit of normal (ULN), Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤1.5 x ULN. In the case of known liver metastasis, ALT and AST（SGOT） ≤1.5 x ULN.

Exclusion Criteria:

* Active uncontrolled central nervous system metastasis
* No adequate organ function or known disease :

  * myocardial infarction
  * active heart disease
  * neuropathy or mental diseases including dementia or epilepsy
  * blind、deaf、dumb or extremity disability
  * known infection
  * active diffuse intravascular coagulation
  * known infection with hepatitis virus
* Pregnant or nursing,fertile patients would not use effective contraception during study treatment
* Prior clinically significant gastrointestinal tract disease , that would influence obviously capecitabine to absorb,including the ability to swallow by the attending physician
* No other active malignancies except that in complete remission with squamous cell carcinoma in situ of the cervix or anus, completely resected basal cell carcinoma, or no recrudescence for at least 2 year from the time a response was first documented
* Having other study medication within 4w
* Having radiation therapy or operation within 4w
* Any non-remission toxicity ≥ CTC 1 in prior anticancer therapy(including radiation therapy) (except alopecie and hemoglobin)
* Peripheral nerve disease ≥ 2
* Previous anaphylactic reaction to Capecitabine and Paclitaxel or diluents bases
* Absence of dihydropyrimidine dehydrogenase
* Patients not suitable determined by the attending physician.